Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy

On February 16, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5221

Related Post

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

Brookfield Asset Management Inc. (TSX:BAM.A) asset management business spinoff

Notice: S&P Dow Jones Indices Announces Changes to the S&P Latin America 40 Index